ProQR Therapeutics NV (PRQR) Receives $30.40 Consensus Price Target from Brokerages

ProQR Therapeutics NV (NASDAQ:PRQR) has earned an average recommendation of “Buy” from the nine analysts that are presently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $30.40.

Several research analysts have weighed in on the company. BidaskClub downgraded ProQR Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 28th. Zacks Investment Research downgraded ProQR Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, March 19th. Royal Bank of Canada assumed coverage on ProQR Therapeutics in a research note on Wednesday, December 19th. They issued an “outperform” rating on the stock. Cantor Fitzgerald reiterated a “buy” rating and issued a $40.00 target price on shares of ProQR Therapeutics in a research note on Thursday, December 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of ProQR Therapeutics in a research note on Thursday, February 28th.

Several institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC boosted its stake in shares of ProQR Therapeutics by 14.1% in the fourth quarter. Geode Capital Management LLC now owns 19,193 shares of the biopharmaceutical company’s stock valued at $302,000 after buying an additional 2,375 shares in the last quarter. FMR LLC boosted its stake in shares of ProQR Therapeutics by 27.8% in the fourth quarter. FMR LLC now owns 1,081,366 shares of the biopharmaceutical company’s stock valued at $17,064,000 after buying an additional 235,053 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of ProQR Therapeutics in the fourth quarter valued at approximately $1,428,000. Legal & General Group Plc purchased a new stake in shares of ProQR Therapeutics in the fourth quarter valued at approximately $1,057,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of ProQR Therapeutics in the fourth quarter valued at approximately $169,000. Hedge funds and other institutional investors own 59.69% of the company’s stock.

Shares of PRQR stock traded down $0.27 during midday trading on Friday, hitting $13.87. The company had a trading volume of 306,961 shares, compared to its average volume of 203,897. ProQR Therapeutics has a 52-week low of $2.90 and a 52-week high of $24.00. The company has a market capitalization of $547.44 million, a P/E ratio of -10.75 and a beta of 0.63. The company has a current ratio of 13.28, a quick ratio of 11.39 and a debt-to-equity ratio of 0.10.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.

Featured Story: Diversification

Analyst Recommendations for ProQR Therapeutics (NASDAQ:PRQR)

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.